Inactive Instrument

Labomar S.p.A.

LBM

IT0005421646

Labomar S p A : AND WELCARE ATTEND ARAB HEALTH 2022

January 25, 2022 at 03:07 pm

This January Labomar and Welcare will join forces to attend Arab Health, the leading medical equipment exhibition in the Middle East, at the Dubai World Trade Center, to create meaningful connections and support innovation in healthcare. Come and visit our booth Z2 H70 - Italian Pavilion. Looking forward to meeting you face-to-face in Dubai, from 24 to 27 January, 2022.

Attachments

Original Link
Original Document
Permalink

Disclaimer

Labomar S.p.A. published this content on 24 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 January 2022 15:06:05 UTC.

Latest news about Labomar S.p.A.

Labomar obtains B CORP certification together with Importfab and Welcare	19/09/23	AN
First Capital exits Labomar and cashes in EUR9 million	07/08/23	AN
LBM Next S.P.A. made a bid to acquire 4.9% stake in Labomar S.p.A. from First Capital S.p.A. for ?9 million.	06/08/23	CI
Europe opens flat; Recordati does well on Mib.	21/07/23	AN
Labomar's revenues grow by double digits in the first half of the year	20/07/23	AN
Mib up slightly, caution reigns in markets	20/07/23	AN
Weak start expected for European indexes	20/07/23	AN
Mib keeps afloat; Nexi closes as best	19/07/23	AN
Labomar board assesses congruous value of LBM Next's takeover bid	04/07/23	AN
Mib in red recovers and goes to 27,000 mark	26/06/23	AN
Milan black jersey; bankers suffer on Mib.	26/06/23	AN
Milan black jersey; bankers suffer on Mib.	26/06/23	AN
Labomar, condition precedent for LBM takeover bid comes true	23/06/23	AN
Futures weak ahead of PMIs; eyes on Juve	23/05/23	AN
Milan just above 27,300; luxury does well	22/05/23	AN
ITALY GROWTH WINNERS & LOSERS: Labomar rises after takeover announcement	22/05/23	AN
LBM-Charterhouse launch takeover bid on Labomar; stock nears offer	22/05/23	AN
Charterhouse Capital Partners LLP agreed to acquire 32% stake in Labomar S.p.A. for â‚¬10 per share	21/05/23	CI
Labomar, first quarter revenues at EUR28 million approx.	20/04/23	AN
Stock markets sluggish; Saipem advances after accounts	20/04/23	AN
Milan up; Chinese bank does not touch rates	20/04/23	AN
Milan rises above 27,900; MPS bullish	19/04/23	AN
Stock exchanges still bullish in wake of Wall Street	30/03/23	AN
Milan best in Europe; stock markets rebound	29/03/23	AN
Labomar, profit drops in 2022 but revenue and Ebitda grow	29/03/23	AN

Chart Labomar S.p.A.

Duration

Period

More charts

Company Profile

LABOMAR S.R.L. is an Italy-based company, which produces dietary supplements, in either solid format or as liquids. The Company's oral solid products include chewable tablets, swallable tablets, coated tablets, gastro-resistant tablets, time release tablets, micro tablets, hard plant or animal gelatine capsules, oro dispersible powders, and water dispersible powders. Its oral liquid products include syrups, hydroglyceric and hydroalcoholic suspensions, solutions, emulsions, and nanoemulsions. The Company serves companies operating in the medical information sector, in distribution channels in chemist and herbalists shops, retail stores of products for athletes and retail organization.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+56.11%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.13%	363B
MERCK & CO., INC.	+15.35%	318B
ABBVIE INC.	+13.01%	299B
ASTRAZENECA PLC	+15.51%	243B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.29%	179B
PFIZER, INC.	+3.98%	167B

Other Pharmaceuticals